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The mean annual incidence of hemolytic uremic syndrome
in persons <15 years of age in Italy from 1988 to 2000 was 0.28
per 100,000 population. Laboratory investigations showed that
Shiga toxin–producing  Escherichia coli (STEC) infection
occurred in 73.1% of patients. STEC O157 was the most com-
mon serotype, but a considerable number of cases were from
infections by non-O157 STEC.
emolytic uremic syndrome (HUS) is the most severe and
specific clinical manifestation of infections with Shiga
toxin (Stx)–producing Escherichia coli (STEC), especially E.
coli O157:H7 and other enterohemorrhagic serotypes; the inci-
dence of HUS represents a robust index of the total incidence
of these infections in a population (1). In Italy, HUS notifica-
tion is not yet mandatory, but a nationwide surveillance system
was established in 1988 and has been followed on a voluntary
basis with the collaboration of the Italian Society for Pediatric
Nephrology. Since then, the HUS surveillance system has been
maintained to monitor the incidence of the disease, describe
those affected, identify the STEC serotypes associated with
HUS, and investigate possible risk factors associated with
STEC infection. 
The Study
The surveillance system was based on all pediatric neph-
rology centers that perform dialytic treatment in Italy. HUS
cases were defined as patients <15 years of age with evidence
of renal failure, intravascular hemolysis, and thrombocytope-
nia (platelet count <100,000/mm3) (2). From May 1988 to
December 2000, a total of 342 HUS cases were reported to the
surveillance system. Twenty-four cases were part of two out-
breaks that occurred in northern Italy in 1992 (3) and 1993 (4),
which were associated with E. coli O111 and E. coli O157
infections, respectively. A third cluster of three cases associ-
ated with E. coli O26 infection occurred in spring 1997 in
Naples, in southern Italy. No outbreak of diarrhea was detected
around these clusters, and no food or environmental source of
infection was identified. The mean incidence per year was
0.28/100,000 population in patients <14 years of age, with a
range of 0.13/100,000 population in 1991 to 0.46/100,000
population in 2000. Since 1994, a steady increase of incidence
has been observed (chi square; p=0.003). We observed the
highest incidence (>0.4/100,000; children <14 years of age) in
the northern part of the country; the lowest incidence was
reported in the insular regions, Sicily and Sardinia. The inci-
dence was higher in children <5 years of age (mean=0.75
cases/100,000 population; range 0.33–1.10). 
The incidence observed in this study is the lowest among
those reported in Europe for the same period (5–10). This find-
ing, together with the rare occurrence of outbreaks (3,4), sug-
gests that STEC infections are relatively uncommon in Italy. In
northern regions, where most cattle farming takes place, the
average annual incidence was similar to that of central Euro-
pean countries. The very low incidence observed in most
regions of southern Italy and in the islands suggests that the
Mediterranean basin is an area with a low incidence of STEC
infection (10,11).
Fifty-one percent of the 342 patients were boys (age range
1 month–14 years; median age 23 months). Of 11 (3.2%)
patients who died, 6 were in the acute phase of HUS. Among
the 274 patients for whom the clinical information was
recorded, prodromal bloody diarrhea was reported in 48%,
nonbloody diarrhea in 30%, and no diarrhea in 22%. In 21% of
cases, diarrhea was reported in other household members
before onset of HUS in the child. In addition, diarrhea among
schoolmates was reported in 7.3% of cases. These findings
suggest that person-to-person transmission may play a major
role in the epidemiology of sporadic HUS cases, as described
in other studies (5,12).
Immediately after diagnosis of HUS, stool samples were
collected from patients and  household contacts when possible.
Specimens were examined for the presence of free fecal Stx by
the Vero cell assay and streaked onto MacConkey agar for
STEC isolation. Serum samples were collected after diagnosis
of HUS and tested for antibodies to the lipopolysaccharide
(LPS) of five major STEC serogroups (O157, O26, O103,
O111, and O145) by enzyme-linked immunosorbent assay as
described (3,13).
Clinical specimens were collected from 249 case-patients.
Stools were obtained from 228 patients and at least one serum
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specimen from 235 patients. The combined use of microbio-
logic and serologic techniques provided evidence of STEC
infection in 182 (73.1%) of 249 cases examined (Table), a per-
centage similar to those reported in similar studies (5,7–
9,14,15).
We documented both microbiologic and serologic evi-
dence of STEC infection in a considerable proportion of
patients who did not have diarrhea (52.4%), although less fre-
quently than in patients with bloody diarrhea (79.3%; chi
square p=0.001) and nonbloody diarrhea (74.6%; p=0.01). A
similar proportion of patients with STEC infection without
diarrhea has also been described in other European studies (7–
9), suggesting that Shiga toxins are able to translocate across
the intestinal mucosa and reach the target endothelial cells
even if the STEC infection does not result in overt diarrhea.
Despite the use of different diagnostic methods, 26.9% of
patients had no evidence of STEC infection. Some patients
may have had an infection caused by a STEC strain belonging
to a serogroup that was not included in the LPS panel used in
this study. In addition, some patients with STEC infection
apparently do not have a serologic response (7).
Stool examination provided evidence of STEC infection in
67 (29.4%) of 228 patients examined. Free fecal Stx was iden-
tified in stool samples from 63 (28.0%) of 225 patients exam-
ined. Most positive samples contained Stx2 alone (47 samples)
or in combination with Stx1 (11 samples). Nineteen STEC
strains were isolated from 18 patients (7.9%); these strains
were from serogroups O157 (6 strains), O111 (4 strains), O26
(2 strains), O55 (2 strains), O86, O113, O118, O120, and
undetermined O (one strain each). The proportion of STEC
recovery from stools, similar to that reported in other studies
(7,14), may be low because of the interval between onset of
diarrhea and stool collection (median 8 days), antimicrobial
therapy administered to many patients before and after the
development of HUS (data not shown), or the freezing, stor-
ing, or shipping of the specimens.
Antibodies to LPS were detected in the sera of 144
(61.3%) of 235 patients examined; in 115, this presence was
the only evidence of STEC infection. Antibodies were
detected to O157 (72 cases), O26 (31 cases), O111 (15 cases),
O145 (15 cases), and O103 (8 cases). Three patients had anti-
bodies to two serogroups: O157 and O26, O26 and O145, and
O26 and O103. 
Serotyping of isolated STEC strains and detection of sero-
group-specific LPS antibodies showed evidence of infection
with STEC O157 in 74 patients. Thirty-four patients had infec-
tion with STEC O26, 17 with STEC O111, 16 with O145, and
9 with O103. As shown in other studies, E. coli O157 was the
most common STEC serogroup associated with HUS. How-
ever, >50% of STEC-positive cases had evidence of infection
with non-O157 STEC. This proportion is higher than that
reported in studies conducted in the United States (14), France
(7), United Kingdom (6), Belgium (8), and the Netherlands
(15) and suggests that the circulation of STEC O157 in Italy is
lower than in other countries.
The distribution of the four most frequent STEC sero-
groups associated with HUS cases by year is shown in the Fig-
ure. Infections with non-O157 serogroups, in particular those
with E. coli O26, increased over time and since 1996 have out-
numbered those with STEC O157. Infections with STEC O111
were frequent from 1990 to 1993, after which they became
rare. This observation emphasizes that the incidence of non-
O157 serotypes may vary over time.
The frequency of STEC O157 infection increased with
age; non-O157 infections were more common in younger chil-
dren. This finding is in agreement with the observation that
non-O157 serotypes were the leading cause of HUS in young
children in Germany (9) and could reflect differences in the
epidemiology or in the pathogenic mechanism of these infec-
tions with respect to those sustained by STEC O157.
For 115 STEC-positive HUS cases, we obtained stool
specimens from 333 household contacts and 119 household
contacts of 36 STEC-negative HUS cases. Laboratory evi-
dence of STEC infection was found in 10 (3.3%) and in 1
(0.8%) of household contacts of STEC-positive and STEC-
negative HUS cases, respectively. Two household contacts
were infected with STEC strains belonging to a serogroup dif-
ferent from that associated with the HUS case. One of 11
STEC-positive household contacts reported diarrhea. Our find-
ings underscore the potential for person-to-person transmis-
sion of STEC infection.
Conclusions
The results of this 13-year surveillance indicate that the
overall incidence of HUS in Italy is lower than in other Euro-
pean countries, although a small but steady increase has been
Table. Evidence of STEC infection in 249 Italian children with HUS, shown by presence of prodromal diarrheaa 
Evidence of STEC infection
Patients with symptoms no. positive/no. examined (%)
Bloody diarrhea Nonbloody diarrhea No diarrhea No information Total
STEC isolation 9/88 (10.2) 4/63 (6.3) 4/39 (10.2) 1/38 (2.6) 18/228 (7.9)
Free fecal Stx 23/86 (26.7) 21/63 (33.3) 10/38 (26.3) 9/38 (23.7) 63/225 (28.0)
Antibodies to LPS 61/88 (69.3) 39/63 (61.9) 14/41 (34.1) 30/43 (69.8) 144/235 (61.3)
Any 73/92 (79.3) 50/67 (74.6) 22/42 (52.4) 37/48 (77.1) 182/249 (73.1)
aSTEC, Shiga toxin–producing Escherichia coli; HUS, hemolytic uremic syndrome; Stx, Shiga toxin; LPS, lipopolysaccharide.DISPATCHES
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observed since 1994. As in most countries, STEC O157 repre-
sented the most common serotype, but a considerable propor-
tion of cases was due to infections by non-O157 STEC,
particularly O26, increasing over the last 5 years. Surveillance
of HUS can provide useful information about the trend of
STEC infection in the general population and represents an
important means to identify STEC serotypes that are highly
pathogenic to humans and may emerge as public health
threats.
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Figure. Distribution of hemolytic uremic syndrome cases associated
with Shiga toxin–producing  Escherichia coli O157, 026, O111, and
O145, by year.